» Articles » PMID: 38961066

The Emerging Role of Nuclear Receptor Coactivator 4 in Health and Disease: a Novel Bridge Between Iron Metabolism and Immunity

Overview
Date 2024 Jul 3
PMID 38961066
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear receptor coactivator 4 (NCOA4) has recently been recognized as a selective cargo receptor of ferritinophagy participating in ferroptosis. However, NCOA4 is also a coactivator that modulates the transcriptional activity of many vital nuclear receptors. Recent novel studies have documented the role of NCOA4 in healthy and pathogenic conditions via its modulation of iron- and non-iron-dependent metabolic pathways. NCOA4 exhibits non-ferritinophagic and iron-independent features such as promoting tumorigenesis and erythropoiesis, immunomodulation, regulating autophagy, and participating in DNA replication and mitosis. Full-length human-NCOA4 is composed of 614 amino acids, of which the N-terminal (1-237) contains nuclear-receptor-binding domains, while the C-terminal (238-614) principally contains a ferritin-binding domain. The exploration of the protein structure of NCOA4 suggests that NCOA4 possesses additional significant and complex functions based on its structural domains. Intriguingly, another three isoforms of NCOA4 that are produced by alternative splicing have been identified, which may also display disparate activities in physiological and pathological processes. Thus, NCOA4 has become an important bridge that encompasses interactions between immunity and metabolism. In this review, we outline the latest advances in the important regulating mechanisms underlying NCOA4 actions in health and disease conditions, providing insights into potential therapeutic interventions.

Citing Articles

Potential applications of gene expression profiles obtained from circulating extracellular vesicles in breast cancer.

Gupta A, Bhardwaj S, Ghorai S, Ahmed R, Agarwal S, Mukherjee G J Liq Biopsy. 2025; 7:100287.

PMID: 40027231 PMC: 11863812. DOI: 10.1016/j.jlb.2025.100287.


Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells.

Colakoglu Bergel C, Eryilmaz I, Cecener G, Egeli U Sci Rep. 2025; 15(1):2422.

PMID: 39827294 PMC: 11742906. DOI: 10.1038/s41598-025-86874-3.

References
1.
Santana-Codina N, Del Rey M, Kapner K, Zhang H, Gikandi A, Malcolm C . NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Cancer Discov. 2022; 12(9):2180-2197. PMC: 9437572. DOI: 10.1158/2159-8290.CD-22-0043. View

2.
Tang M, Huang Z, Luo X, Liu M, Wang L, Qi Z . Ferritinophagy activation and sideroflexin1-dependent mitochondria iron overload is involved in apelin-13-induced cardiomyocytes hypertrophy. Free Radic Biol Med. 2019; 134:445-457. DOI: 10.1016/j.freeradbiomed.2019.01.052. View

3.
Santoro M, Dathan N, Berlingieri M, Bongarzone I, Paulin C, Grieco M . Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994; 9(2):509-16. View

4.
Wahli W, Michalik L . PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012; 23(7):351-63. DOI: 10.1016/j.tem.2012.05.001. View

5.
Bellelli R, Castellone M, Guida T, Limongello R, Dathan N, Merolla F . NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. Mol Cell. 2014; 55(1):123-37. DOI: 10.1016/j.molcel.2014.04.031. View